5 Key Takeaways
-
1
The prevalence of dry eye disease (DED) exceeds 20 million in the U.S. and 350 million globally, highlighting its significant impact.
-
2
Recent advancements in ocular surface disease (OSD) treatments include novel mechanisms targeting inflammation and tear production.
-
3
Bausch + Lomb's Miebo and Tarsus Pharmaceutical's Xdemvy represent innovative approaches to treating evaporative eye disease and Demodex blepharitis.
-
4
Emerging therapies, such as AbbVie's reproxalap and Alcon's AR-15512, focus on novel inflammatory pathways and improved patient compliance.
-
5
The future of OSD treatment promises targeted therapies and enhanced diagnostics, aiming to improve outcomes for millions suffering from chronic conditions.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.